Switzerland · Delayed Price · Currency is CHF Achilles Therapeutics Statistics
Total Valuation
SWX:ZURN has a market cap or net worth of CHF 81.67 billion. The enterprise value is 90.21 billion.
| Market Cap | 81.67B |
| Enterprise Value | 90.21B |
Important Dates
The last earnings date was Thursday, August 7, 2025.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | Apr 11, 2025 |
Share Statistics
SWX:ZURN has 142.29 million shares outstanding. The number of shares has decreased by -1.11% in one year.
| Current Share Class | 142.29M |
| Shares Outstanding | 142.29M |
| Shares Change (YoY) | -1.11% |
| Shares Change (QoQ) | -0.74% |
| Owned by Insiders (%) | 0.23% |
| Owned by Institutions (%) | 33.25% |
| Float | 141.95M |
Valuation Ratios
The trailing PE ratio is 17.75 and the forward PE ratio is 14.96. SWX:ZURN's PEG ratio is 2.54.
| PE Ratio | 17.75 |
| Forward PE | 14.96 |
| PS Ratio | 1.47 |
| PB Ratio | 3.88 |
| P/TBV Ratio | 8.36 |
| P/FCF Ratio | 16.00 |
| P/OCF Ratio | 15.03 |
| PEG Ratio | 2.54 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.34, with an EV/FCF ratio of 17.67.
| EV / Earnings | 19.38 |
| EV / Sales | 1.63 |
| EV / EBITDA | 12.34 |
| EV / EBIT | 12.86 |
| EV / FCF | 17.67 |
Financial Position
The company has a current ratio of 13.32, with a Debt / Equity ratio of 0.60.
| Current Ratio | 13.32 |
| Quick Ratio | 5.88 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 1.72 |
| Debt / FCF | 2.46 |
| Interest Coverage | 20.71 |
Financial Efficiency
Return on equity (ROE) is 24.09% and return on invested capital (ROIC) is 13.39%.
| Return on Equity (ROE) | 24.09% |
| Return on Assets (ROA) | 1.47% |
| Return on Invested Capital (ROIC) | 13.39% |
| Return on Capital Employed (ROCE) | 2.27% |
| Revenue Per Employee | 923,612 |
| Profits Per Employee | 77,580 |
| Employee Count | 60,000 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, SWX:ZURN has paid 1.78 billion in taxes.
| Income Tax | 1.78B |
| Effective Tax Rate | 26.36% |
Stock Price Statistics
The stock price has increased by +23.41% in the last 52 weeks. The beta is 0.57, so SWX:ZURN's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | +23.41% |
| 50-Day Moving Average | 561.15 |
| 200-Day Moving Average | 561.28 |
| Relative Strength Index (RSI) | 62.32 |
| Average Volume (20 Days) | 181,383 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SWX:ZURN had revenue of CHF 55.42 billion and earned 4.65 billion in profits. Earnings per share was 32.34.
| Revenue | 55.42B |
| Gross Profit | 12.21B |
| Operating Income | 7.02B |
| Pretax Income | 6.77B |
| Net Income | 4.65B |
| EBITDA | 7.15B |
| EBIT | 7.02B |
| Earnings Per Share (EPS) | 32.34 |
Balance Sheet
The company has 5.42 billion in cash and 12.57 billion in debt, giving a net cash position of -7.16 billion or -50.32 per share.
| Cash & Cash Equivalents | 5.42B |
| Total Debt | 12.57B |
| Net Cash | -7.16B |
| Net Cash Per Share | -50.32 |
| Equity (Book Value) | 21.04B |
| Book Value Per Share | 137.87 |
| Working Capital | 32.42B |
Cash Flow
In the last 12 months, operating cash flow was 5.43 billion and capital expenditures -327.66 million, giving a free cash flow of 5.11 billion.
| Operating Cash Flow | 5.43B |
| Capital Expenditures | -327.66M |
| Free Cash Flow | 5.11B |
| FCF Per Share | 35.88 |
Margins
Gross margin is 22.03%, with operating and profit margins of 12.66% and 8.40%.
| Gross Margin | 22.03% |
| Operating Margin | 12.66% |
| Pretax Margin | 12.21% |
| Profit Margin | 8.40% |
| EBITDA Margin | 12.91% |
| EBIT Margin | 12.66% |
| FCF Margin | 9.21% |
Dividends & Yields
This stock pays an annual dividend of 28.00, which amounts to a dividend yield of 4.85%.
| Dividend Per Share | 28.00 |
| Dividend Yield | 4.85% |
| Dividend Growth (YoY) | 7.69% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 80.16% |
| Buyback Yield | 1.11% |
| Shareholder Yield | 5.95% |
| Earnings Yield | 5.70% |
| FCF Yield | 6.25% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |